GSK-Nuvalent Oncology Biotech Repricing
GSK's $10.6 billion acquisition of Nuvalent — its largest deal in eight years — is triggering a broad repricing of M&A premium potential across oncology-focused biotech peers including Incyte, Johnson & Johnson, and Petrobras-linked healthcare proxies, as investors reassess competitive positioning and acquisition target valuations across the cancer drug landscape.
stockscommodities
Verwandte Assets
| Vermögenswert | Preis | 24h Veränderung | Sektor |
|---|---|---|---|
GSKGSK plc | $53.05 | +0.25% | general |
HYPEHyperliquid | $60.1 | +2.28% | — |
JAP225Nikkei 225 Index | $67,106 | +1.41% | asia indices |
XAUUSDGold / US Dollar | $4,238.95 | +0.65% | precious metals |
GBPUSDBritish Pound / US Dollar | $1.34 | -0.08% | forex majors |
GILDGilead Sciences Inc | $125.51 | -0.28% | healthcare |
IRENIREN Limited | $59.69 | +5.22% | general |
LLYEli Lilly and Company | $1,140.75 | -1.31% | healthcare |
CHKPCheck Point Software Technologies Ltd. | $126.32 | +0.00% | tech |
MGMMGM Resorts International | $48.92 | +3.58% | general |
MSFTMicrosoft Corp. | $391.84 | -0.35% | tech |
INCYIncyte Corporation | $97.07 | +0.00% | general |
JNJJohnson & Johnson | $240.64 | +0.88% | healthcare |
SOLSolana | $68.27 | +1.40% | — |
IBRXImmunityBio, Inc. | $8.16 | +0.00% | general |
OMCOmnicom Group Inc. | $76.51 | +0.79% | general |
SLNOSoleno Therapeutics, Inc. | $53.02 | +0.00% | — |
PATHUiPath Inc. | $10.53 | -1.36% | general |
WHEATWheat | $5.79 | -0.34% | agriculture |
EURUSDEuro / US Dollar | $1.16 | -0.07% | forex majors |
Verwandte Sektoren
Bereit zum Handeln?
Handeln Sie Assets zum Thema GSK-Nuvalent Oncology Biotech Repricing mit bis zu 2.000x Hebel auf CoinUnited.io.
Auf CoinUnited.io traden →